VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- PMID: 20006922
- DOI: 10.1016/j.ejca.2009.11.001
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Abstract
Proteinuria is a dose-related side-effect occurring after inhibition of vascular endothelial growth factor (VEGF) signalling and may reflect severe glomerular damage. The inhibition of the VEGF signalling axis induces downexpression or suppression of nephrin, an important protein for the maintenance of the glomerular slit diaphragm, sometimes leading to nephritic syndrome and/or glomerular thrombotic microangiopathy, the main-associated kidney disease. A MEDLINE search was carried out using the following criteria: (1) all MEDLINE listings as of 01-01-2000 with abstracts; (2) English language; and (3) Humans. The following phrases were used to query the database: (proteinuria) AND (anti-VEGF OR VEGF inhibition OR bevacizumab OR sunitinib OR sorafenib OR VEGF Trap OR axitinib OR pazopanib OR AZ 2171). The references of each article identified were carefully reviewed for additional reference. The incidence of mild and asymptomatic proteinuria ranges from 21% up to 63%, but heavy proteinuria has been reported in up to 6.5% of renal cell carcinoma patients. Although discontinuation of anti-VEGF agent induced significant reduction, persistence of proteinuria is common. Although angiotensinconverting-enzyme inhibitors and/or angiotensin receptor blockers seem to be preferred, no specific recommendation for an antiproteinuric agent can be made in this context because there are no controlled studies addressing the subject. Periodic monitoring of urinary protein should be carried out in anti-VEGF-treated patients and patients showing proteinuria need special referral to nephrologists.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.Anticancer Drugs. 2009 Jan;20(1):81-2. doi: 10.1097/CAD.0b013e3283161012. Anticancer Drugs. 2009. PMID: 19343005
-
Renal effects of anti-angiogenesis therapy: update for the internist.Am J Med. 2009 Apr;122(4):322-8. doi: 10.1016/j.amjmed.2008.11.025. Am J Med. 2009. PMID: 19332223 Review.
-
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.Am J Kidney Dis. 2007 Aug;50(2):203-18. doi: 10.1053/j.ajkd.2007.04.025. Am J Kidney Dis. 2007. PMID: 17660022 Review.
-
[Nephrotoxicity--proteinuria and hypertension--].Gan To Kagaku Ryoho. 2008 Oct;35(10):1649-53. Gan To Kagaku Ryoho. 2008. PMID: 18931564 Japanese.
-
Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.Semin Nephrol. 2010 Nov;30(6):582-90. doi: 10.1016/j.semnephrol.2010.09.006. Semin Nephrol. 2010. PMID: 21146123
Cited by
-
Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.BMC Nephrol. 2019 Jan 11;20(1):14. doi: 10.1186/s12882-018-1194-9. BMC Nephrol. 2019. PMID: 30634936 Free PMC article.
-
Castleman disease mimicking systemic lupus erythematosus: A case report.Medicine (Baltimore). 2018 Sep;97(38):e12291. doi: 10.1097/MD.0000000000012291. Medicine (Baltimore). 2018. PMID: 30235674 Free PMC article.
-
Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.Front Pharmacol. 2021 Dec 9;12:744776. doi: 10.3389/fphar.2021.744776. eCollection 2021. Front Pharmacol. 2021. PMID: 34955823 Free PMC article.
-
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.Thorac Cancer. 2018 May;9(5):613-620. doi: 10.1111/1759-7714.12627. Epub 2018 Mar 25. Thorac Cancer. 2018. PMID: 29575760 Free PMC article.
-
Guidelines for treatment of renal injury during cancer chemotherapy 2016.Clin Exp Nephrol. 2018 Feb;22(1):210-244. doi: 10.1007/s10157-017-1448-z. Clin Exp Nephrol. 2018. PMID: 28856465 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources